SCLP.LSE Scancell Hldgs Plc

Healthcare Biotechnology London Exchange
0.8640 GBX
Close of Nov 3, 2026
86.00 295.00
Market cap
GBX 117M
P/E
-
P/B
8.89x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Apr 2026.

Is SCLP.LSE undervalued?

Graham number

The Graham number of Scancell Hldgs Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Scancell Hldgs Plc fundamental analysis

No fundamental analysis for Scancell Hldgs Plc yet.

Scancell Hldgs Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Scancell Hldgs Plc

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. The company's product candidates include ImmunoBody, DNA active immunotherapies encode a protein in the form of a modified antibody; Moditope, a potent peptide active immunotherapy targeting tumour-specific neoantigens through the MHC-II presentation pathway; SCIB1 which is in phase I for adjuvant melanoma; SCIB1/iSCI…

Full company profile